Pralatrexate - Antifolate - 生命科學試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPralatrexateCat. No.: HY-10446CAS No.: 146464-95-1分式: CHNO分量: 477.47作靶點: Antifolate作通路: Cell Cycle/DNA Damage儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 50 mg/mL (104.72 mM)* means solu

2、ble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.0944 mL 10.4719 mL 20.9437 mL5 mM 0.4189 mL 2.0944 mL 4.1887 mL10 mM 0.2094 mL 1.0472 mL 2.0944 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍?，配制前請先配制澄清的儲備液，再依次添加助溶?為保證實驗結(jié)果的可靠性，體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，

3、當天使；澄清的儲備液可以根據(jù)儲存條件，適當保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.24 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.24 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEB

4、IOLOGICAL ACTIVITY物活性 Pralatrexate(Folotyn)葉酸類似物，對些細胞株的 IC50 300 nM。戶使本產(chǎn)品發(fā)表的科研獻 J Mol Med (Berl). 2019 Jun 14.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutso

5、ukos T,OConnor OA.,Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup EfficacyAnalysis From the PROPEL Study,Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43. Epub 2012 Apr 26.2. Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D,

6、Pereira JR, Juhsz E, Iannotti NO, Weems G, Koutsoukos T, PatelJD.,Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) afterfailure of prior platinum-based therapy.,J Thorac Oncol. 2012 Jun;7(6):1041-8.3. Horwitz SM, Kim YH, Fos

7、s F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, KoutsoukosT, Saunders ME, OConnor OA, Duvic M.,Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractorycutaneous T-cell lymphoma.,Blood. 2012 May 3;119(18):411

8、5-22. Epub 2012 Mar 6.4. Casanova M, Medina-Prez A, Moreno-Beltran M, Mata-Vazquez M, Rueda A.,Critical appraisal of pralatrexate in the management ofdifficult-to-treat peripheral T cell lymphoma.,Ther Clin Risk Manag. 2011;7:401-8. Epub 2011 Oct 7.5. Hui J, Przespo E, Elefante A.,Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and otherpotential uses.,J Oncol Pharm Pract. 2012 Jun;18(2):275-83. Epub 2011 Sep 26.McePdfHeightCaution: Product has not been fully validated for medical appl